SOPHiA GENETICS Q4 Revenue Rises 22% While Net Loss Widens 27%
SOPHiA GENETICS reported Q4 2025 revenue of $21.7 million, up 22% year-over-year, while EPS missed at –$0.28 versus an estimate of –$0.25. Despite a 140-basis-point adjusted gross margin expansion to 73.9%, IFRS net loss widened 27% to $19.2 million and adjusted EBITDA loss rose 9% to $9.9 million.
1. Q4 Financial Results
In Q4 2025, SOPHiA GENETICS generated revenue of $21.7 million, a 22% increase year-over-year, but reported EPS of –$0.28, missing the –$0.25 estimate. This mismatch reflects ongoing challenges in balancing growth with profitability.
2. Margin Improvement
Gross margin for the quarter improved to 67.7% on a reported basis and 73.9% on an adjusted basis, marking a 140-basis-point expansion in adjusted gross profit. This improvement underscores the scalability of the SOPHiA DDMTM AI-native precision medicine platform.
3. Losses Increase
Despite higher revenue and margin gains, IFRS net loss widened by 27% to $19.2 million, and adjusted EBITDA loss rose by 9% to $9.9 million. Rising operating costs and investment in platform development contributed to the deeper losses.
4. Full-Year Performance and Valuation
For the full year 2025, the company achieved $77.3 million in revenue, up 19%, while IFRS net loss climbed 26% to $79 million and adjusted EBITDA loss increased 3% to $41.5 million. Key valuation metrics include a price-to-sales ratio of 3.99, an enterprise-value-to-sales ratio of 3.74, and a current ratio of 2.80, offset by a negative EV/operating cash flow ratio of –7.15.